External medicine composite for treating psoriasis
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- XIAMEN ENCHENG PHARMA CO LTD
- Publication Date
- 2017-10-27
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Description
technical field
[0001] The invention relates to an external pharmaceutical composition for treating psoriasis. More specifically, the present invention relates to a pharmaceutical composition for external use containing tazarotene and urea. Background technique
[0002] Psoriasis, commonly known as psoriasis, is a common chronic relapse-prone inflammatory skin disease with characteristic skin lesions. Induced in sensitive individuals. Pathological changes include excessive hyperplasia and incomplete differentiation of skin keratinocytes, infiltration of inflammatory cells, and dilation of dermal blood vessels. The clinical manifestations are mainly erythema and scales; the skin lesions are red papules and macules of different sizes, with multiple layers of dry white silver scales on them, and patients often feel itchy. It can occur in any part of the human body, but it is more common on the scalp and extremities, and it is usually aggravated in winter. Harm: In addition ...